Introduction
In patients with acute chest pain, early diagnosis of an acute myocardial infarction (MI) [1] [2] [3] [4] and optimal risk stratification 5, 6 depend on cardiac troponin levels measured by high-sensitivity assays in addition to clinical assessment and electrocardiogram (ECG). 7, 8 In spite of the progress made in the management of acute coronary syndrome (ACS) patients, the diagnosis of MI remains challenging in patients presenting with symptoms of unstable angina (UA) and a substantial residual risk of mortality and morbidity remains, 9 warranting novel pathophysiological insights into the early events at the onset of ACS. Triggers of acute coronary thrombotic occlusion followed by myocardial ischaemia and necrosis are key factors in the development of ACS. Thus, a soluble biomarker reflecting early events before myocardial necrosis occurs would provide an incremental tool towards the timely diagnosis of this high-risk patient population, thereby helping towards improving their prognosis. Cysteine-rich angiogenic inducer 61 (Cyr61, CCN1) is a member of the CCN family of matricellular proteins exerting critical functions in angiogenesis, inflammation, and fibrotic tissue repair [10] [11] [12] [13] [14] and serves as a ligand for activated platelets binding to integrin a IIb ß 3 .
15
Cyr61 is an immediate early gene product expressed in response to a variety of stimuli such as mechanical stretch/shear stress, 16 hypoxia, 17, 18 tumour necrosis factor-a, 19, 20 transforming growth factorb, 17, 19, 21 and platelet-derived growth factor.
21
Cyr61 is involved in angiogenesis and cardiovascular disease. Indeed, Cyr61 knockout mice undergo embryonic lethality due to impaired vascular integrity during placental development and atrioventricular septal defects. 22, 23 Cyr61 mediates endothelial proliferation, tubule formation, and neovascularization in an integrin-dependent manner 24, 25 and promotes recruitment of CD34 þ progenitor cells to the endothelium. 26 In vitro studies show that Cyr61 mediates monocyte adhesion and activation of a pro-inflammatory gene profile consistent with M1-type macrophages that are involved in the early phase of ACS. 27, 28 In a mouse model of autoimmune myocarditis, Cyr61 modulated recruitment of monocytes and lymphocytes to the inflamed myocardium. 29 Inhibition of Cyr61 in experimental models of carotid balloon injury decreased proliferation of vascular smooth muscle cells and in turn intimal hyperplasia. 30, 31 In humans, increased expression of Cyr61 was detected in areas of atherosclerotic lesions rich in vascular smooth muscle cells and in cardiomyocytes of patients with ischaemic cardiomyopathy. 32, 33 The diagnostic and prognostic value of Cyr61 as a biomarker in ACS patients remains unknown. In this study, we hypothesized that gene expression profiling in coronary thrombi and peripheral blood mononuclear cells obtained from ACS patients would identify candidate gene transcripts central to the pathophysiology of acute coronary thrombotic occlusion and/ or myocardial injury. After identification of transcripts of the secreted protein cysteine-rich angiogenic inducer 61 (Cyr61, CCN1) in coronary thrombi of ACS patients and myocardium in a mouse model of ischaemia-reperfusion, we evaluated its diagnostic and prognostic value in ACS patients, patients with hypertrophic obstructive cardiomyopathy (HOCM) after transcoronary ablation of septal hypertrophy and in a primary prevention cohort.
Methods

Patient characteristics and tissue/blood sampling
Patients with an acute coronary syndrome to assess diagnostic and prognostic performance
The SPUM-ACS cohort consists of consecutive patients referred for coronary angiography with the main diagnosis of ACS to one of the participating university hospitals (Bern, Geneva, Lausanne, and Zurich; all in Switzerland) enrolled in the Special Programme University Medicine Acute Coronary Syndromes and Inflammation (SPUM ACS; NCT01000701). [34] [35] [36] [37] [38] [39] Inclusion criteria comprised all females and males aged 18 years and older presenting within 5 days (preferably within 72 h) after pain onset with the main diagnosis of ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or UA. Included patients had symptoms compatible with angina pectoris (chest pain and dyspnoea) and fulfilled at least one of the following criteria: (i) persistent ST-segment elevation or depression, T-inversion, or dynamic ECG changes, new left bundle branch block (LBBB); (ii) evidence of positive troponin by local laboratory reference values (with a rise and/or fall in serial troponin levels); (iii) known coronary artery disease, specified as status after myocardial infarction, coronary artery bypass grafting (CABG), or percutaneous coronary intervention (PCI) or newly documented > _50% stenosis of an epicardial coronary artery during the initial catheterization. Exclusion criteria comprised severe physical disability, inability to comprehend study or <1 year of life expectancy (for non-cardiac reasons). Clinical and angiographic data (presence of coronary thrombus 39 documented on a priori defined forms)
were entered on electronic case report forms and stored in a web-based electronic database. Follow-up was performed at 30 days (phone call) and 1 year (clinical visit) with events adjudicated by three independent experts using pre-specified adjudication forms.
Patients with stable coronary disease as a reference cohort Venous blood was collected at the initial visit, and serum aliquots were frozen at -80 C until measurement. We nested a case-control study with 75 cases defined as individuals who died (all-cause mortality) or experienced an MI during follow-up and 287 controls. All individuals enrolled in the different cohorts provided written informed consent in compliance with the Declaration of Helsinki, and all studies were approved by the local research ethics committees.
Biomarker measurement and analysis
Concentrations of Cyr61 were measured in duplicates of single serum aliquots blinded to the patient's data by means of numbered ID codes using a semi-automated solid phase enzyme-linked immunosorbent assay (EIA-5108, DRG Instruments GmbH, Marburg, Germany) in SPUM-ACS and sCAD patients. The inter-and intra-assay coefficients of variation in SPUM-ACS patients were 3.22% and 3.47%, respectively. Troponin T was measured in serum aliquots using a high-sensitivity assay (hsTnT) from the SPUM-ACS cohort using electrochemiluminescence immunoassays analysed on a cobas e 602 reader (all Roche Diagnostics, Mannheim, Germany) 38 with assay characteristics as reported by the manufacturer.
Clinical endpoints and risk score calculation
The primary endpoint was all-cause mortality within 30 days after the index ACS and at 1 year follow-up. The secondary endpoint comprised the composite of all-cause mortality or non-fatal recurrent MI as described. 38 The Global Registry of Acute Coronary Events (GRACE)
risk score was used to calculate both, in-hospital, 41 and long-term 42 predictions of mortality and to assess the degree of disease severity in ACS patients included in this study.
Gene expression array
Total RNA of freshly isolated coronary thrombi and corresponding peripheral blood mononuclear cells from 15 ACS patients was isolated using commercially available Qiagen RNeasy V R Mini Kit (Qiagen, Hombrechtikon, Switzerland) according to the manufacturer's instructions. The concentration, purity, and integrity of the isolated total RNA were determined using a NanoDrop V R ND1000 (NanoDrop Technologies, Wilmington, DE, USA) and a Bioanalyzer 2100 (Agilent Technologies, Basel, Switzerland). Quantitatively and qualitatively best RNA samples from a total of four patients were used for complementary DNA synthesis following standard protocols and submitted to the local core facility (Functional Genomics Center, University Zurich, Zurich, Switzerland) for processing and analysis (Human Genome U133 Plus 2.0 Affymetrix Gene Chip TM from Affymetrix, Inc. Santa Clara, CA, USA). The microarray expression data were preprocessed with the statistics software R 43 using the RMA method as implemented in the Affymetrix package. Differential expression analysis was performed with the moderated t-statistic and false discovery rate (FDR) multiple-test correction methods of the limma package. Transcripts with an FDR < _0.1 and absolute linear fold change of > _2 were considered as significantly differentially expressed. The raw microarray expression data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO series accession number GSE19339 [http://www. ncbi.nlm.nih.gov/geo (27 October 2017)]. 35 The differentially expressed genes were clustered according to their annotation using the DAVID Bioinformatics Resource to identify significantly enriched functional annotation terms in the categories gene ontology and pathways and each cluster were assigned an arbitrary title based on best fit. 44 
Statistical analyses
Clinical characteristics of each group are presented as means with standard deviations and P-values from t-tests for continuous variables. Categorical variables were shown as counts with percentages and P-values from the v 2 or the Fisher's exact tests. We compared medians of Cyr61 between different groups of patients using P-values from the Wilcoxon rank-sum test and its extension Kruskal-Wallis. We compared the area under the receiver operating characteristics (ROC) curves as a measure of diagnostic accuracy to detect coronary thrombus between Cyr61 and hsTnT. Time-to-first event was analysed throughout, censoring patients at 30 days or 365 days, or at last valid contact date, whichever came first. We used a Cox proportional hazards regression model to evaluate possible associations between the two biomarkers and all-cause mortality and the composite of all-cause mortality or recurrent MI (at 30 days and 1 year follow-up), using continuous, log-transformed biomarker values and continuous GRACE scores. The added predictive ability of the new predictor over and above a reference model was assessed by Harrell's C-statistics calculated from a Cox proportional hazards regression model and integrated discrimination improvement (IDI) index based on logistic model, 45 using the GRACE risk score as reference. The P-value of the C-statistics comparing new with reference model was derived from a likelihood ratio test used for the Cox models.
In the nested case-control study, comparison of Cyr61 levels between cases and controls was analysed using linear and logistic regression. Crude and multivariable-adjusted models were applied. Multivariable models were adjusted for gender, age (continuous), smoking (never, former, current), body mass index (continuous), hypertension (yes/no), diabetes (yes/no), LDL cholesterol (continuous), and log-transformed creatinine (continuous) in multivariable models. All analyses were performed using Stata V R version 14.1 (Stata Corp, College Station, TX, USA).
Cyr61 in acute myocardial injury
Results
Identification of Cyr61 in coronary thrombi of acute coronary syndrome patients
To assess differentially expressed genes involved in acute coronary thrombotic occlusion, a global gene expression array was performed on messenger RNA isolated from coronary thrombi aspirated from the culprit lesion in the infarct-related coronary artery and PBMCs from individual ACS patients undergoing pPCI. Among candidate gene transcripts with a significant increase in expression in coronary thrombi, Cyr61 was identified as highly differentially expressed (66-fold increase) (Figure 1) . Increased protein expression of Cyr61 was found on the surface of T lymphocytes in coronary thrombi compared with PBMC (see Supplementary material online, Figures S1 and S2 , Table S1 ). In human coronary plaques, Cyr61 expression was localized within lesions rich in CD68
þ cells (see Supplementary material online, Figure S3 ).
Cyr61 at clinical presentation with acute coronary syndrome
Cyr61 serum levels were measured in 1592 patients with STEMI, NSTEMI/UA, and stable CAD, respectively ( Figure 2A) . Cyr61 was markedly elevated in patients with STEMI compared with NSTEMI/ UA or stable CAD, respectively. Among 2168 ACS patients enrolled in the SPUM-ACS cohort, 1740 had complete data on Cyr61 and hsTnT (see Supplementary material online, Figure S4 ). The clinical characteristics of these patients are shown in Table 1 and see  Supplementary material online, Tables S2-S4 . When stratified by the onset of chest pain, Cyr61 levels were highest in early presenters (< _6 h) ( Table 2 ). In a subset of 1641 patients with data on angiographic presence or absence of coronary thrombus and biomarkers, diagnostic accuracy of Cyr61 was superior to hsTnT for detecting coronary thrombi (Figure 3 ), albeit at a moderate sensitivity and specificity (see Supplementary material online, Table S5 ). Furthermore, Cyr61 levels were significantly higher in 904 patients with STEMI compared with 737 with NSTEMI, irrespective of whether coronary thrombi were present ( Figure 2B ). Based on the latter finding, we analysed myocardial expression of Cyr61 in a mouse model of ischaemia-reperfusion injury (see Supplementary material online, Figure S5 ) and the release kinetics of Cyr61 upon septal branch occlusion during transcoronary ablation of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy (see Supplementary material online, Figure S6 , see Supplementary material online, Tables S6 and S7).
Prognostic value of Cyr61 in acute coronary syndrome patients
Among 1740 ACS patients enrolled in the SPUM-ACS study with Cyr61 and hsTnT measured, follow-up data were available in 99.1% of patients at 30 days and 95.8% at 1 year, respectively (see Supplementary material online, Figure S4 , Table S2 and Table 1 ). All-cause mortality occurred in 33 cases (1.9%) at 30 days, and in a further 73 cases (4.2%) up to 1 year follow-up; the composite of allcause mortality or MI was ascertained in 59 cases (3.4%) at 30 days and in 130 cases (7.5%) up to 1 year follow-up (see Supplementary material online, Table S8 ).
Cox regression analysis demonstrated a significant and independent association between elevated Cyr61 concentration and all-cause mortality at 30 days and at 1 year follow-up (Table 3 and see  Supplementary material online, Table S9 ). When combined with the reference GRACE risk score (C-statistic 0.77), Cyr61 provided incremental information to predict 1 year all-cause mortality (C-statistic 0.80, P < 0.001) comparable to the combination of the GRACE risk score with hsTnT (C-statistic 0.79, P < 0.001). Combining both biomarkers with the GRACE risk score provided similar accuracy to predict 1 year all-cause mortality (C-statistic 0.80, P < 0.001). Similar results were obtained for the composite endpoint of all-cause mortality or MI at 1 year follow-up ( Table 4) .
Prognostic value of Cyr61 in a population-based case-control cohort
In a prospective case-control cohort of a total 362 individuals from a large prospective cohort (CoLaus) followed up for 5.4 years, we identified 75 cases (21 cardiovascular deaths, 16 other deaths, and 38 MIs) and selected 287 matched controls for the analysis. The concentration of Cyr61 was not statistically different between cases and controls ( Table 5) .
Discussion
Based on gene expression profiling in coronary thrombi and peripheral blood mononuclear cells, we have demonstrated for the first time that (i) Cyr61 expression is markedly increased in coronary thrombi of ACS patients aspirated from the infarct-related coronary artery and in myocardium from mice subjected to ischaemiareperfusion; (ii) soluble Cyr61 represents a novel early biomarker detecting acute myocardial injury in HOCM patients; (iii) at presentation Cyr61 concentration was the highest in STEMI patients compared with NSTEMI patients, which, in turn, was higher than in stable CAD patients, irrespective of the presence of coronary thrombi; and (iv) soluble Cyr61 improves risk stratification of ACS patients for allcause mortality and the composite endpoint of all-cause mortality or MI beyond the commonly used clinical GRACE risk score.
Gene expression profiling of coronary thrombi compared with peripheral blood mononuclear cells was used to screen for novel gene transcripts involved at the site of the acute coronary occlusion. We found a markedly increased expression of the matricellular protein Cyr61 in coronary thrombi in ACS patients with a predominant expression on T lymphocytes. In line with these findings, immunohistology studies of atherosclerotic coronary arteries demonstrated increased expression of Cyr61 in the shoulder region of plaques adjacent to regions infiltrated by macrophages. In contrast, human internal mammary arteries free of atherosclerosis did not express the protein. Our findings extend data on the expression of Cyr61 in stable human atherosclerotic plaques 32 and further imply a role of the protein in plaque stability early on during acute coronary occlusion. Furthermore, in a large all-comer ACS cohort, serum levels of soluble Cyr61 in peripheral blood were markedly increased compared with patients with stable CAD (Figure 2A ). In patients with angiographic evidence of coronary thrombus, Cyr61 exhibited only moderate diagnostic accuracy with an area under the curve of 0.65 which, however, surpassed that of troponin. A limitation is related to the high thrombus burden necessary to enable visual detection of coronary thrombus in epicardial vessels by coronary angiography unlike high-resolution intravascular imaging modalities. 46 However, irrespective of whether a coronary thrombus was angiographically visible or not, Cyr61 was significantly higher in STEMI patients compared to those with NSTEMI/UA compared with stable CAD patients suggesting that myocardial injury is the primary trigger of Cyr61 release. In line with this interpretation, Cyr61 expression levels were markedly increased in a mouse model of ischaemia-reperfusion injury using coronary ligation and in patients with HOCM undergoing TASH; both conditions that are characterized by severe myocardial injury in the absence of coronary thrombus formation. Interestingly, soluble Cyr61 was rapidly released after septal occlusion in HOCM patients and was detectable prior to troponin, which exhibited a delayed and persistent release within the first 24 h. These data are in support of the concept that the novel biomarker Cyr61 is involved in the initial stages of ACS reflecting myocardial injury. As Cyr61 gene expression is increased in response to hypoxia, 17, 18 it may indeed be a biomarker of myocardial ischaemia, but more research is warranted to address this issue in more detail. One in 6 patients experienced a major adverse cardiovascular event within the first year after an ACS as defined as a composite endpoint of cardiac death, infarction, revascularization, stent thrombosis, or stroke (see Supplementary material online, Table S8 ). However, the identification of those at highest risk remains suboptimal, despite it being of great clinical relevance. Indeed, particularly with the advent of novel and expensive drugs such as PCSK9 inhibitors, optimal identification of high-risk patients is ever more relevant. Values are expressed as n (%) or means ± standard deviations. CABG, coronary artery bypass graft; CAD, coronary artery disease; LMWH, lowmolecular-weight heparin; PCI, percutaneous coronary interventions; TIA, transient ischaemic attack. a Based on creatinine-estimated glomerular filtration rate clearance of <60 mL/ min/1.73m 2 , using the modification of diet in renal disease formula. Thus, better prediction of clinical outcome beyond currently available biomarkers and clinical risk scores is an unmet need in the care of patients after an ACS. 9 Importantly, we here show that Cyr61 improves risk stratification for all-cause mortality and for the composite endpoint of all-cause mortality or MI beyond that provided by the currently used GRACE risk score, which incorporates clinical parameters as well as cardiac troponin. When combined with the GRACE risk score, Cyr61 provided incremental prognostic accuracy comparable to adding hsTnT ( Table 4 ). This suggests that clinical information including troponin in the GRACE risk score, as it is routinely used currently does not fully reflect the risk for both, all-cause mortality and myocardial infarction. Interestingly, troponin T concentrations as measured with a highsensitivity assay were significantly associated with the incidence of cardiovascular death and heart failure but not with myocardial infarction in patients with stable CAD. 47 Thus, it appears that unlike troponin T the novel biomarker Cyr61 can predict death as well as recurrent MI, reflecting a myocardial and an atherothrombotic pathophysiology. A limitation of this study is the rather low number of events in this contemporary cohort warranting validation in other cohorts in the future. Conversely, in individuals from a population-based case-control cohort followed up for 5.4 years Cyr61 did not predict major adverse cardiovascular events suggesting that myocardial injury is a prerequisite for Cyr61 to provide prognostic information. 
Limitations
In SPUM-ACS, only patients referred for coronary angiography with an established main diagnosis of ACS were included. Thus, the role of Cyr61 in patients presenting with chest pain to the emergency room remains to be elucidated and prospective validation in large well characterized ACS cohorts is necessary. Data in this study are based on a single measurement of Cyr61 at the time of coronary angiography. Future studies will need to address optimal timing of Cyr61 measurement for the diagnosis of myocardial injury and risk stratification.
In this study, we cannot provide data on whether Cyr61 remains useful for patients with chronic inflammatory disease or malignancy, warranting further analysis.
Conclusions
Our data highlight Cyr61 as a novel soluble biomarker of acute myocardial injury, providing incremental information beyond currently available tools for risk stratification in ACS patients. Results are expressed as average ± standard deviation or as a number of participants (%) for the bivariate analysis and as multivariable-adjusted average ± standard error or odds ratio (95% confidence interval) for multivariable analysis. Statistical analysis by v 2 or logistic regression for categorical data and by analysis of variance for continuous data. a Adjusted for gender, age (continuous), smoking (never, former, current), body mass index (continuous), hypertension (yes/no), diabetes (yes/no), LDL cholesterol (continuous), and log-transformed creatinine (continuous). 
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